# Coordinator Log — Atrial Fibrillation (Multi-DB)

## 2026-04-14 — Run Initialization

**Action:** Archived prior run to `atrial_fibrillation_pre_20260414`.

The prior run was a single-DB run targeting only `synthetic_pcornet`. This new
run targets both `synthetic_pcornet` and `nhanes` per `db_triage.json`.

**DB Triage Summary:**
- `synthetic_pcornet` (PCORnet Synthetic CDW): disposition=RUN, mode=online, engine=duckdb
  - Warning: Conventions file missing; protocols may miss DB-specific rules.
- `nhanes` (NHANES): disposition=RUN, mode=online, engine=duckdb

Both DBs have disposition=RUN (not RUN_AUTO_ONBOARD), so Phase 0 onboarding
generation is not needed — just verification.

---

## Phase 1: Literature Discovery — ACCEPTED

**Discovery worker (attempt 1):** Ran out of 15 turns before writing deliverables.
**Discovery worker (attempt 2):** Completed successfully with 49 PMIDs, 7 ranked
questions (scores 5-9), three-pass search strategy.

**Reviewer findings:** 3 issues identified —
1. Liu 2025 (PMID 41121356) direction of effect reversed (worker: "lower mortality",
   actual: higher mortality RR 1.21). Corrected in Sections 2 and 7.
2. Missed TTE study PMID 36252244 (apixaban vs rivaroxaban in AF+VHD). Added to
   Sections 1 and 8. Q1 TTE novelty reduced from 2→1, gap score 9→8.
3. CLOSURE-AF (PMID 41849741) mischaracterized as "pending" — actually showed LAAC
   NOT noninferior. Corrected in Section 6.

**Decision:** ACCEPT with corrections applied. Top 3 questions unchanged:
1. Apixaban vs rivaroxaban in AF + advanced CKD (gap score 8)
2. Catheter ablation vs AADs in AF + HFpEF (gap score 8)
3. DOACs vs warfarin in AF + liver cirrhosis (gap score 8)

All 7 questions approved for feasibility (Q7 excluded — TTE already exists).

---

## Phase 2: Feasibility — ACCEPTED (with pivot)

### synthetic_pcornet: INFEASIBLE (all 6 questions)
500-patient synthetic test dataset. Key findings from database queries:
- 50 AF patients (I48.91 only), 0 DOACs, 0 warfarin, 0 AADs
- 0 catheter ablations, 0 LAAC procedures
- 0 advanced CKD (stages 4-5), 0 HFpEF, 0 cirrhosis, 0 dialysis
- 0 stroke/SE events, 0 major bleeding events
- Only 27 medications (statins, aspirin, metoprolol, metformin, etc.)
**Decision:** Mark synthetic_pcornet as failed/infeasible. Drop from later phases.

### nhanes: INFEASIBLE for all 6 original TTE questions
Cross-sectional survey with no longitudinal follow-up, no procedure codes, no
medication doses, no new-user designs possible. Key counts (3-cycle pooled):
- 17,192 adults examined, 421 anticoagulant users (258 warfarin, 69 apixaban, 66 rivaroxaban)
- 12 anticoagulant users with eGFR < 30 (too small for CKD-specific TTE)
- ~130 AC users with eGFR < 60
- Mortality linkage available (up to 6 years, through 12/31/2019)

**Pivot:** NHANES feasibility worker recommended alternative analysis:
"Prevalent anticoagulant use (DOAC vs warfarin) → all-cause mortality in CKD subgroups"
using NHANES mortality linkage. This is a prevalent-user design with acknowledged
limitations, but it's the best this data supports and is clinically relevant to Q1.

**Decision:** Proceed to protocol generation for NHANES with the alternative question.
No questions feasible on ≥2 DBs for replication analysis.

---

## Phase 3: Protocol Generation — ACCEPTED (with corrections)

### nhanes Protocol 01: DOAC vs Warfarin → All-Cause Mortality in CKD (Prevalent-User)
- Design: Prevalent-user cohort, NHANES 2013-2018 pooled, mortality linkage
- Population: AC users with eGFR < 60 (~130 participants)
- Exposure: Current DOAC vs current warfarin
- Outcome: All-cause mortality (NDI linkage through 12/31/2019)
- Methods: Survey-weighted IPW Cox PH, WeightIt, cobalt, E-value

**Reviewer verdict: REVISE (3 MUST FIX, 2 SHOULD FIX)**
1. eGFR missing 1.012 female multiplier → FIXED in code and protocol
2. Income (INDFMPIR) omitted from PS model → ADDED to ps_candidates
3. MI history missing from protocol confounder table → ADDED
4. Unused tbl1_svy survey object → REMOVED
5. E-value rare flag unconditional → MADE conditional on event rate

All 5 corrections applied by coordinator. Protocol ACCEPTED.

---

## Phase 4: Execution & Reporting — COMPLETE

### Execution
- **Attempt 1:** Failed — nhanesA factor encoding (RIDSTATR = factor not numeric),
  MCQ230D type conflict across cycles. Worker found issues but ran out of turns.
- **Coordinator fixes:** Updated script with `translate=FALSE`, explicit `as.numeric()`,
  MCQ column selection. Script saved.
- **Attempt 2:** Succeeded after one in-flight fix (lonely PSU: `survey.lonely.psu="adjust"`).
  
**Results:**
- CONSORT: 17,192 → 391 → 361 → 130 → 129 → **125** final (46 DOAC, 79 warfarin)
- **HR = 1.07 (95% CI: 0.57-2.02), p = 0.84** — no significant difference
- 53 deaths (14 DOAC, 39 warfarin), median follow-up 30 months
- Balance: max SMD 1.056 → 0.125 post-IPW
- Sensitivity: unadjusted HR = 1.19 (0.60-2.37); E-value = 1.27
- All publication outputs generated (Table 1, love plot, PS dist, KM, CONSORT)

### Report
- Written by report worker, all numbers verified against results JSON
- 5 literature citations with PMIDs
- Prominent prevalent-user and design limitation caveats

---

## Executive Summary — WRITTEN

Cross-DB synthesis written to `summary.md`. Key conclusions:
- Neither DB was feasible for the 6 original TTE questions
- NHANES pivot yielded null result (HR 1.07, p=0.84) — expected given prevalent-user design
- Synthetic PCORnet dropped (infeasible)
- Single hypothesis tested — no FDR correction needed
- Recommendations: use longitudinal claims/EHR databases for these AF questions

**Pipeline complete.** 10 sub-agents launched, 0 backtracks, 0 revision cycles.

---
